ReviewFrontiers in immunology2013
Inhibition of HLA-DM Mediated MHC Class II Peptide Loading by HLA-DO Promotes Self Tolerance.
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- BPM Exposure Induces Pulmonary Dysfunction in Adult Mice and Adverse Intergenerational Pulmonary Effects in Offspring.Environment & health (Washington, D.C.) · 2026Article
- Respiratory syncytial virus inhibits type I interferon signaling to maintain HLA-DM expression in CD1ciScience · 2026Article
- Identification of a type 1 diabetes-associated T cell receptor repertoire signature from the human peripheral blood.Science advances · 2026Article
- Sterile production of interferons in the thymus.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- H2-O deficiency promotes regulatory T cell differentiation and CD4 T cell hyperactivity.Frontiers in immunology · 2023Article
- Role of B cells as antigen presenting cells.Frontiers in immunology · 2022Review
- Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.Frontiers in immunology · 2022Review
- Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.Current opinion in immunology · 2021Review
- Genetic Control of Neonatal Immune Tolerance to an Exogenous Retrovirus.Journal of virology · 2020Article
- How a Proposed Hypothesis during My PhD Training Shaped My Career.Critical reviews in immunology · 2020Article
- Selection of immunodominant epitopes during antigen processing is hierarchical.Molecular immunology · 2019Review
- Class II MHC antigen processing in immune tolerance and inflammation.Immunogenetics · 2019Review
- Ancient features of the MHC class II presentation pathway, and a model for the possible origin of MHC molecules.Immunogenetics · 2019Review
- High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.Frontiers in oncology · 2019Article
- Patient HLA Germline Variation and Transplant Survivorship.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Neutralizing Antibody Responses to Viral Infections Are Linked to the Non-classical MHC Class II Gene H2-Ob.Immunity · 2017Article
- The Other Function: Class II-Restricted Antigen Presentation by B Cells.Frontiers in immunology · 2017Review
- Human leukocyte Antigen-DM polymorphisms in autoimmune diseases.Open biology · 2016Review
- CD4 T cell epitope specificity determines follicular versus non-follicular helper differentiation in the polyclonal response to influenza infection or vaccination.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Major histocompatibility class II (MHCII) molecules are loaded with peptides derived from foreign and self-proteins within the endosomes and lysosomes of antigen presenting cells (APCs). This process is mediated by interaction of MHCII with the conserved, non-polymorphic MHCII like molecule HLA-DM (DM). DM activity is directly opposed by HLA-DO (DO), another conserved, non-polymorphic MHCII like molecule. DO is an MHCII substrate mimic. Binding of DO to DM prevents MHCII from binding to DM, thereby inhibiting peptide loading. Inhibition of DM function enables low stability MHC complexes to survive and populate the surface of APCs. As a consequence, DO promotes the display of a broader pool of low abundance self-peptides. Broadening the peptide repertoire theoretically reduces the likelihood of inadvertently acquiring a density of self-ligands that is sufficient to activate self-reactive T cells. One function of DO, therefore, is to promote T cell tolerance by shaping the visible image of self. Recent data also shows that DO influences the adaptive immune response by controlling B cell entry into the germinal center reaction. This review explores the data supporting these concepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.